This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Travere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
by Ekta Bagri
Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
by Zacks Equity Research
The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing product expires.
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -5.71% and 53.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of 21.43% and 1.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 50% and 7.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
IDEAYA Biosciences (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)
by Zacks Equity Research
Liquidia Technologies (LQDA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) delivered earnings and revenue surprises of 5.45% and 2.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arvinas (ARVN) delivered earnings and revenue surprises of 34.46% and 18.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Liquidia Technologies (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -82.61% and 14.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 81.07% and 47.01%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 54.70%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -90.23% and 210.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies (DVAX) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 71.4% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 29.94%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 29.9% upside potential for Liquidia Technologies, Inc. (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Liquidia Technologies, Inc. (LQDA) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Liquidia Technologies, Inc. (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -111.76% and 0.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?